Reunion Neuroscience

Reunion Neuroscience is a clinical-stage biopharmaceutical company developing patented serotonergic psychedelic therapeutics for underserved mental health disorders. The company's lead candidate, luvesilocin — the only 4-OH-DiPT prodrug in clinical development — is designed as a fast-acting, short-duration therapy and achieved its primary endpoint in the Phase 2 REKINDLE trial for postpartum depression (PPD), earning Breakthrough Therapy Designation from the FDA. Reunion is advancing luvesilocin into a pivotal Phase 3 trial for PPD in 2026, alongside Phase 2 studies in adjustment disorder and generalized anxiety disorder. The company was spun out of Field Trip Health Ltd. and is headquartered in Toronto, Canada.